Time Variability of C-Reactive Protein: Implications for Clinical Risk Stratification
暂无分享,去创建一个
G. Dagenais | J. Brophy | L. Joseph | P. Belisle | P. Bogaty | L. Boyer | A. Leblanc
[1] F. Crea,et al. High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases: a multiethnic case-control study. , 2011, Journal of the American College of Cardiology.
[2] A. Hingorani,et al. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial , 2011, European heart journal.
[3] Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study , 2011, The Lancet.
[4] Zahi A Fayad,et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Journal of the American College of Cardiology.
[5] David M. Reboussin,et al. A 1-Year Lifestyle Intervention for Weight Loss in Individuals With Type 2 Diabetes Reduces High C-Reactive Protein Levels and Identifies Metabolic Predictors of Change , 2010, Diabetes Care.
[6] J. Danesh,et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.
[7] Robert Dufour,et al. Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .
[8] L. Smeeth,et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. , 2009, International journal of epidemiology.
[9] P. Ridker,et al. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. , 2009, Clinical chemistry.
[10] G. Dagenais,et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. , 2008, Journal of the American College of Cardiology.
[11] Lisa M. Schwartz,et al. Distribution of C-reactive protein values in the United States. , 2005, The New England journal of medicine.
[12] G. Dagenais,et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. , 2005, Archives of internal medicine.
[13] Jing Ma,et al. Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.
[14] François Mach,et al. Inflammation and Atherosclerosis , 2004, Herz.
[15] G. Dagenais,et al. Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein: A Randomized Placebo-Controlled Study , 2004, Circulation.
[16] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.
[17] T. Badrick,et al. Limited clinical utility of high-sensitivity plasma C-reactive protein assays , 2002, Annals of clinical biochemistry.
[18] G. Dagenais,et al. Biological Profiles in Subjects With Recurrent Acute Coronary Events Compared With Subjects With Long-Standing Stable Angina , 2001, Circulation.
[19] P. Ridker,et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. , 2001, Clinical chemistry.
[20] M. Pfeffer,et al. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .
[21] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[22] L. Kuller,et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. , 1999, American journal of epidemiology.
[23] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[24] C. Kluft,et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[25] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[26] C. Fraser,et al. Biological Variation of Acute Phase Proteins , 1993, Annals of clinical biochemistry.
[27] Mark B Pepys,et al. C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.
[28] L. Shaw,et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.
[29] M. Pfeffer,et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. , 1999, Circulation.
[30] R. Tracy,et al. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.
[31] A. Raftery,et al. Bayes factors , 1995 .